1.Clinical significance of interleukin-17 producing cell infiltration with TGF-β1 expression in glioma
Guanhua ZHANG ; Yonggao MOU ; Xiangheng ZHANG ; Xiaobing JIANG ; Zhongping CHEN
Chinese Journal of Behavioral Medicine and Brain Science 2011;20(5):407-409
Objective To investigate correlation between the amount of interleukin-17 (IL-17) producing cells and the expression of transforming growth factor (31 (TGF-β1) in glioma,and evaluate the clinical values of IL-17 and TGF-pl in predicting the prognosis of glioma. Methods The presence of IL-17 and TGF-pl was measured by immunohistochemistry in 135 human glioma (WHO Ⅰ 18,WHO Ⅱ 45,WHO Ⅲ 53,WHO Ⅳ 19) tissues and 15 normal brain tissues. Results There was no IL-17 positive staining in normal brain tissues. Of 135 glioma specimens showed low TGF-pl expression and 77 (57. 03% ) showed high TGF-pl expression. No TGF-β1 expression was detected in normal brain tissue. Furthermore,TGF-β1 expression was positively correlated with the amount of IL-17 producing cells in glioma tissues ( r=0.285, P<0.01). Compared with the low grade,the levels of IL-17 and TGF-pl positive cells were obviously increased in high grade. The Kaplan-Meier analysis showed that there were significant differences in overall survival (OS) between the IL-17 and TGF-pl high-expression and lowexpression group (P<0.01, P<0.05). The 3-year OS rates of IL-17 of high expression and low expression were 33.75% and 76. 36%. Multivariate Cox proportional hazards regression analysis indicated that age,KPS score, IL-17 were independent prognostic factor for OS (P<0.01). Conclusion Intratumoral IL-17-producing cell density and the expression of TGF-β1 was associated with the malignancy of human glioma.
2.Recent advance in clinical researches of islet organoids for treating type 1 diabetes mellitus
Boya ZHANG ; Xiangheng CAI ; Shusen WANG
Chinese Journal of Organ Transplantation 2024;45(9):641-645
Type 1 diabetes mellitus (T1DM) is a multifactorial autoimmune disease and T1DM patients require insulin therapy. Capable of delaying the process of diabetic microangiopathy and lowering diabetes-related mortality, islet transplantation has become an ideal treatment of T1DM. However, islet transplantation is severely limited by an acute shortage of donor pancreas. In recent years, islet regeneration is gaining popularity. This review focused upon an overview of cell sources of islet organoids, optimization methods for islet organoids culture and research advances in clinical applications, providing references for clinical transformation of islet organoids for T1DM.